Line 4: |
Line 4: |
| {{Under Construction}} | | {{Under Construction}} |
| | | |
− | <blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-11-03. The original page can be found at [[HAEM4:Chronic Neutrophilic Leukemia (CNL)]]. | + | <blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-11-30. The original page can be found at [[HAEM4:Chronic Neutrophilic Leukemia (CNL)]]. |
| }}</blockquote> | | }}</blockquote> |
| ==Primary Author(s)*== | | ==Primary Author(s)*== |
Line 16: |
Line 16: |
| __TOC__ | | __TOC__ |
| | | |
− | ==Cancer Category/Type== | + | ==Cancer Category / Type== |
| | | |
| [[Myeloproliferative Neoplasms (MPN)|Myeloproliferative Neoplasms]] | | [[Myeloproliferative Neoplasms (MPN)|Myeloproliferative Neoplasms]] |
Line 149: |
Line 149: |
| The presenting features may be non-specific with organomegaly involving the liver, spleen or both, mucocutaneous bleeding, and bruising.<ref name=":0" /> The disease has a variable prognosis with some cases rapidly evolving<ref name=":6" /><ref>{{Cite journal|last=Zittoun|first=R.|last2=Réa|first2=D.|last3=Ngoc|first3=L. H.|last4=Ramond|first4=S.|date=1994-02|title=Chronic neutrophilic leukemia. A study of four cases|url=https://pubmed.ncbi.nlm.nih.gov/8148416|journal=Annals of Hematology|volume=68|issue=2|pages=55–60|doi=10.1007/BF01715131|issn=0939-5555|pmid=8148416}}</ref>; others may have an indolent course spanning decades.<ref>{{Cite journal|last=Uppal|first=Guldeep|last2=Gong|first2=Jerald|date=2015-09|title=Chronic neutrophilic leukaemia|url=https://pubmed.ncbi.nlm.nih.gov/26082513|journal=Journal of Clinical Pathology|volume=68|issue=9|pages=680–684|doi=10.1136/jclinpath-2015-203060|issn=1472-4146|pmid=26082513}}</ref> Survival is variable, overall mean survival being between 21-30 months. | | The presenting features may be non-specific with organomegaly involving the liver, spleen or both, mucocutaneous bleeding, and bruising.<ref name=":0" /> The disease has a variable prognosis with some cases rapidly evolving<ref name=":6" /><ref>{{Cite journal|last=Zittoun|first=R.|last2=Réa|first2=D.|last3=Ngoc|first3=L. H.|last4=Ramond|first4=S.|date=1994-02|title=Chronic neutrophilic leukemia. A study of four cases|url=https://pubmed.ncbi.nlm.nih.gov/8148416|journal=Annals of Hematology|volume=68|issue=2|pages=55–60|doi=10.1007/BF01715131|issn=0939-5555|pmid=8148416}}</ref>; others may have an indolent course spanning decades.<ref>{{Cite journal|last=Uppal|first=Guldeep|last2=Gong|first2=Jerald|date=2015-09|title=Chronic neutrophilic leukaemia|url=https://pubmed.ncbi.nlm.nih.gov/26082513|journal=Journal of Clinical Pathology|volume=68|issue=9|pages=680–684|doi=10.1136/jclinpath-2015-203060|issn=1472-4146|pmid=26082513}}</ref> Survival is variable, overall mean survival being between 21-30 months. |
| </blockquote> | | </blockquote> |
− | ==Individual Region Genomic Gain/Loss/LOH== | + | ==Individual Region Genomic Gain / Loss / LOH== |
| | | |
| Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span> | | Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span> |
Line 229: |
Line 229: |
| | | |
| </blockquote> | | </blockquote> |
− | ==Gene Mutations (SNV/INDEL)== | + | ==Gene Mutations (SNV / INDEL)== |
| | | |
| Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span> | | Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span> |